
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Timber Pharma Updates TMB-001 Development For Congenital Ichthyosis
Details : MB-001 is an investigational topical ointment formulation of isotretinoin for the potential treatment of patients with moderate to severe congenital ichthyosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2024
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Leo Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
LEO Pharma Finalizes Acquisition of Key Assets from Timber Pharmaceuticals
Details : LEO expands its pipeline by acquiring TMB-001, an investigational topical reformulation of isotretinoin, which is currently only available orally in the U.S.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 23, 2024
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Leo Pharma
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Leo Pharma
Deal Size : $36.0 million
Deal Type : Acquisition
LEO Pharma Signs Agreement to Acquire Timber Pharmaceutical
Details : Through the acquisition, LEO gains rights to establish TMB-001, topical isotretinoin in Timber's patented IPEG™ delivery system, as the standard of care in the treatment of congenital ichthyosis, a devastating, rare disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $14.0 million
August 21, 2023
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Leo Pharma
Deal Size : $36.0 million
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TMB-001 (isotretinoin) inhibits sebaceous gland function and keratinization at pharmacologic doses. It is being developed for the treatment of X-Linked recessive ichthyosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2023
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TMB-001 is a topical isotretinoin, formulated using IPEG™ delivery system, in development for the treatment of moderate to severe forms of congenital ichthyosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 25, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TMB-001 is a topical isotretinoin, formulated using the Company’s patented IPEG™ delivery system, in development for the treatment of moderate to severe forms of congenital ichthyosis (CI) including ARCI and X-linked recessive ichthyosis (XLRI).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TMB-001 is a topical isotretinoin formulation in development based on the Company’s patented IPEG™ delivery system for the treatment of moderate to severe forms of congenital ichthyosis (CI).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $8.0 million
Deal Type : Public Offering
Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering
Details : The Company intends to use the net proceeds from this offering for research and development, including clinical trials of TMB-001 having isotretinoin, working capital and general corporate purposes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 08, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $8.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TMB-001 0.05%, a topical isotretinoin formulated using patented IPEG™ delivery system, for treatment of moderate to severe forms of congenital ichthyosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 23, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the Phase 2b CONTROL study, treatment with TMB-001 (Isotretinoin) demonstrated a clinically meaningful reduction in targeted and overall severity of CI along with a favorable safety profile.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
